Basilea Pharmaceutica AG

SIX:BSLN.SW

43.65 (CHF) • At close November 4, 2024
Bedrijfsnaam Basilea Pharmaceutica AG
Symbool BSLN.SW
Munteenheid CHF
Prijs 43.65
Beurswaarde 529,088,896
Dividendpercentage 0%
52-weken bereik 32 - 47.95
Industrie Biotechnology
Sector Healthcare
CEO Mr. David Veitch
Website https://www.basilea.com

An error occurred while fetching data.

Over Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and

Vergelijkbare Aandelen

Ascom Holding AG logo

Ascom Holding AG

ASCN.SW

4.63 CHF

COLTENE Holding AG logo

COLTENE Holding AG

CLTN.SW

56.4 CHF

IVF Hartmann Holding AG logo

IVF Hartmann Holding AG

VBSN.SW

143 CHF

SHL Telemedicine Ltd. logo

SHL Telemedicine Ltd.

SHLTN.SW

8.9 CHF

Relief Therapeutics Holding AG logo

Relief Therapeutics Holding AG

RLF.SW

6.1 CHF

Molecular Partners AG logo

Molecular Partners AG

MOLN.SW

5.06 CHF

Evolva Holding SA logo

Evolva Holding SA

EVE.SW

0.94 CHF

Kuros Biosciences AG logo

Kuros Biosciences AG

KURN.SW

27.3 CHF

Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A.

NWRN.SW

8 CHF

Financiële Gegevens

Cijfers zijn in miljoenen (CHF)

Cijfers zijn in miljoenen (CHF)